Recent studies illuminate new molecular mechanisms and targets across various cancer types. Research identifies EMP1 as a driver in pancreatic cancer progression, CYP26A1 enzyme linked to folate metabolism emerges as a promising target in colorectal cancer, and TCF3 transcription factor is implicated in bladder cancer through ferroptosis regulation. Additionally, new PROTAC compounds degrade estrogen receptor and IKZF1 proteins, representing novel cancer therapeutic strategies. A study also connects basal metabolic rate with hepatocellular carcinoma progression, offering fresh metabolic perspectives.